Abstract
Transmission clusters of HIV-1 subtype B uniquely associated with the epidemic among men who have sex with men (MSM) in East Asia have recently been identified. Using the Los Alamos HIV sequence database and the UK HIV drug resistance database, we explored possible links between HIV MSM epidemics in East Asia and the rest of the world by using phylogenetic and molecular clock analyses. We found that JP.MSM.B-1, a subtype B MSM variant that accounts for approximately one-third of the infections among Japanese MSM, was detected worldwide, in the United Kingdom (n=13), mainland China (n=3), the United States, Germany, Canada, and Taiwan (n=1 each). Interestingly, 10 United Kingdom samples plus two from Germany and the United States formed a distinct monophyletic subgroup within JP.MSM.B-1. The estimated divergence times of JP.MSM.B-1 and the latter subgroup were ~1989 and ~1999, respectively. These dates suggest that JP.MSM.B-1 was circulating for many years in Japan among MSM before disseminating to other countries, most likely through global MSM networks. A significant number of other Asian MSM HIV lineages were also detected in the UK HIV drug resistance database. Our study provides insight into the regional and global dispersal of Asian MSM HIV lineages. Further study of these strains is warranted to elucidate viral migration and the interrelationship of HIV epidemics on a global scale.
| Original language | English |
|---|---|
| Pages (from-to) | 9864-9876 |
| Number of pages | 13 |
| Journal | Journal of Virology |
| Volume | 88 |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - 2014 |
Bibliographical note
Funding Information:This study was supported by a grant-in-aid for AIDS research from the Ministry of Health, Labor, and Welfare of Japan, as well as by the United Kingdom Medical Research Council (grant G0900274) and the European Community's 7th framework program (FP7/2007-2013) under the Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN; project 223131), and in part by international grants from the Daiwa Anglo-Japanese Foundation (O.G.P. and Y.T.) and from the Japan China Medical Association (Y.T.). The collaborators contributing to the UKHIVRDB are as follows: steering committee members Celia Aitken (Gartnavel General Hospital, Glasgow), David Asboe, Anton Pozniak (Chelsea and Westminster Hospital, London), Patricia Cane (Public Health England, Porton Down), Hannah Castro, David Dunn (cochair), David Dolling, Esther Fearnhill, Kholoud Porter, Anna Tostevin (MRC Clinical Trials Unit at University College London, London), David Chadwick (South Tees Hospitals NHS Trust, Middlesbrough), Duncan Churchill (Brighton and Sussex University Hospitals NHS Trust), Duncan Clark (St. Bartholomew's and The London NHS Trust), Simon Collins (HIV i-Base, London), Valerie Delpech (Centre for Infections, Public Health England), Samuel Douthwaite (Guy's and St. Thomas' NHS Foundation Trust, London), Anna Maria Geretti (Institute of Infection and Global Health, University of Liverpool), Antony Hale (Leeds Teaching Hospitals NHS Trust), St?phane Hu? (University College London), Steve Kaye (Imperial College, London), Paul Kellam (Wellcome Trust Sanger Institute and University College London Medical School), Linda Lazarus (Expert Advisory Group on AIDS Secretariat, Public Health England), Andrew Leigh Brown (University of Edinburgh), Tamyo Mbisa (Virus Reference Department, Public Health England), Nicola Mackie (Imperial NHS Trust, London), Chloe Orkin (St. Bartholomew's Hospital, London), Deenan Pillay (cochair), Andrew Phillips, Caroline Sabin (University College London Medical School, London), Erasmus Smit (Public Health England, Birmingham Heartlands Hospital), Kate Templeton (Royal Infirmary of Edinburgh), Peter Tilston (Manchester Royal Infirmary), Daniel Webster (Royal Free NHS Trust, London), Ian Williams (Mortimer Market Centre, London), Hongyi Zhang (Addenbrooke's Hospital, Cambridge), and Mark Zuckerman (King's College Hospital, London). The centers contributing data are the Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge (Jane Greatorex); Guy's and St. Thomas' NHS Foundation Trust, London (Siobhan O'Shea, Jane Mullen); PHE-Public Health Laboratory, Birmingham Heartlands Hospital, Birmingham (Erasmus Smit); PHE-Virus Reference Department, London (Tamyo Mbisa); Imperial College HealthNHSTrust, London (Alison Cox); King's College Hospital, London (Richard Tandy); Medical Microbiology Laboratory, Leeds Teaching Hospitals NHS Trust (Tracy Fawcett); Specialist Virology Centre, Liverpool (Mark Hopkins, Lynn Ashton); Department of Clinical Virology, Manchester Royal Infirmary, Manchester (Peter Tilston); Department of Virology, Royal Free Hospital, London (Claire Booth, Ana Garcia-Diaz); Edinburgh Specialist Virology Centre, Royal Infirmary of Edinburgh (Jill Shepherd); Department of Infection and Tropical Medicine, Royal Victoria Infirmary, Newcastle (Matthias L. Schmid, Brendan Payne); South Tees Hospitals NHS Trust, Middlesbrough (David Chadwick); Department of Virology, St. Bartholomew's and The London NHS Trust (Spiro Pereira, Jonathan Hubb); Molecular Diagnostic Unit, Imperial College, London (Steve Kaye); University College London Hospitals (Stuart Kirk); and the West of Scotland Specialist Virology Laboratory, Gartnavel, Glasgow (Alasdair MacLean, Celia Aitken, and Rory Gunson). The coordinating center was the Medical Research Council Clinical Trials Unit (Hannah Castro, Kate Coughlin, David Dunn, David Dolling, Esther Fearnhill, Lorraine Fradette, Kholoud Porter, Anna Tostevin, and Ellen White). We have no conflicts of interest to report.
Publisher Copyright:
© 2014, American Society for Microbiology. All Rights Reserved.
